Insights from Krista Pinto on access, AI, and the shift to integrated commercialization
Following Asembia 2026, a clear picture is emerging of what matters most to pharmaceutical leaders today.
In a recent interview with pharmaphorum, Krista Pinto, a commercialization expert at EVERSANA, shared insights from more than 70 conversations with clients and prospects — highlighting how priorities are evolving across access, outsourcing, and AI.
Read the full interview in pharmaphorum
Access Is Now a Core Commercial Strategy
One of the most consistent themes from Asembia is the growing importance of patient access, affordability, and speed‑to‑therapy.
Access is no longer viewed as a support function. It has become a core differentiator — directly influencing patient outcomes and overall brand performance. As a result, manufacturers are looking for ways to reduce friction, improve coordination, and ensure patients can begin therapy faster.
The Rise of Integrated Commercialization Models
As commercialization becomes more complex, companies are moving away from fragmented approaches and toward more integrated, end‑to‑end partnerships.
Rather than relying on multiple vendors, organizations are seeking partners who can bring together strategy, execution, and infrastructure — helping them scale efficiently while navigating pricing pressure and regulatory demands.
This shift is also changing how outsourcing is viewed. It’s no longer about filling gaps, but about building long‑term, strategic partnerships that deliver measurable impact across the product lifecycle.
AI Is Moving from Hype to Application
AI was a central topic across nearly every discussion at Asembia — but the nature of those conversations is changing.
Manufacturers are no longer asking what AI is. They’re asking how it can be applied in practical, compliant ways to deliver real results.
The focus is now on proven use cases, including:
- Forecasting
- Patient identification
- Operational efficiency
More importantly, AI is increasingly expected to be embedded into core workflows — not layered on as a separate initiative.
What Comes Next
The takeaway from Asembia 2026 is clear: success in today’s environment requires connected, scalable, and execution‑focused commercialization models.
Organizations that can integrate access, data, AI, and execution — while maintaining focus on patient outcomes — will be best positioned to lead in an increasingly complex market.
Learn more about EVERSANA COMPLETE Commercialization®
Author Team
EVERSANA employs a team of over 6000 professionals across 20+ locations around the world. From industry-leading patient service and adherence support to global pricing and revenue management, our team informs the strategies that matter…